CDKN2B-AS1 and cancer: Amongst this subtype, ANRIL was elevated in 25–40% of cases, associated with a poorer prognosis, and was included as part of a three non-coding RNA signature proposed for distinguishing triple negative breast cancer from other cancer types (15).